Autoimmune Disease News and Research

RSS

Autoimmune Disease is a condition in which the body recognizes its own tissues as foreign and directs an immune response against them.

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.

25 May 2011

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

Seattle Genetics, Inc. today announced that data from its brentuximab vedotin and SGN-75 programs will be reported at the upcoming American Society of Clinical Oncology 2011 Annual Meeting being held June 3-7, 2011 in Chicago, IL.

21 May 2011

African Americans with SLE have higher antibody response to influenza vaccination: Study

New research shows that African Americans with systemic lupus erythematosus had a higher antibody response to influenza vaccination than European American patients.

21 May 2011

EMA CHMP issues positive opinion for marketing approval of BENLYSTA

GlaxoSmithKline and Human Genome Sciences, Inc. announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion, recommending marketing authorisation for BENLYSTA (belimumab) as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus, with a high degree of disease activity, despite standard therapy.

20 May 2011

Thermo Fisher Scientific to acquire Phadia for €2.47 billion

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has signed a definitive agreement to acquire Phadia, a global leader in allergy and autoimmunity diagnostics, from European private equity firm Cinven, for €2.47 billion (or approximately $3.5 billion) in cash.

From Thermo Fisher Scientific Inc. 19 May 2011

USPTO grants four key patents for Alvine's proteases to detect celiac disease

Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, today announced that the United States Patent and Trademark Office has issued four key patents: 7,943,312; 7,928,056; 7,923,532; and 7,910,541, protecting various aspects of Alvine's core technology.

19 May 2011

Amylin, JDRF collaborate to investigate combination therapy for type 1 diabetes treatment

The Juvenile Diabetes Research Foundation and Amylin Pharmaceuticals, Inc. announced today that they have entered into a research collaboration agreement to provide financial support for a series of clinical studies to investigate the feasibility of mixing pramlintide, an analog of the human hormone amylin, with insulin to treat type 1 diabetes.

11 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Nexvax2- coeliac disease vaccine shows promising results in Phase I clinical trial

The world's first potential vaccine for coeliac disease has shown promising results for treating coeliac disease in a Phase I clinical trial and is expected to move to Phase II trials within the next year.

10 May 2011

Season-of-birth factors can cause celiac disease in Massachusetts children

Celiac disease is more common among Massachusetts children born in the spring or summer, and this higher incidence could be related to the intersection of key seasonal and environmental factors, according to researchers at the Massachusetts General Hospital for Children.

9 May 2011

Lupus Foundation of America introduces new Web site

To coincide with Lupus Awareness Month this May, the Lupus Foundation of America is launching a new Web site, Lupus Voices Across America™, that will allow people with lupus and their supporters to share their lupus stories.

3 May 2011

FDA accepts SGEN's brentuximab vedotin BLAs for Hodgkin lymphoma, ALCL treatment

Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration has accepted for filing two Biologics License Applications for brentuximab vedotin, including one for the treatment of patients with relapsed or refractory Hodgkin lymphoma and one for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma.

2 May 2011

Journal Blood publishes MacroGenics' DART antibody technology preclinical data

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent inhibition of B-cell lymphoma through redirected T lymphocyte-mediated killing, using its bispecific DART antibody technology.

29 Apr 2011

Study explores link between alexithymia and auto-immune disease

This paper, which explores the link between the inability to express emotions and an auto-immune disease, failed to find any statistical significant associations.

29 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

Pfizer Inc. announced today top-line results from the ORAL Standard and ORAL Step Phase 3 studies of tofacitinib, an investigational, novel, oral JAK inhibitor.

29 Apr 2011

Study finds gender difference in immune responses to PTSD

Men and women had starkly different immune system responses to chronic post-traumatic stress disorder, with men showing no response and women showing a strong response, in two studies by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.

27 Apr 2011

Researchers discover molecular mechanisms behind autoimmunity

Researchers from Boston University School of Medicine have discovered that human proteins with an affinity for Dermatan Sulfate have the propensity to become autoantigens. In a companion article, the researchers also found that DS physically interacts with dead cells and that the resulting DS-autoantigen complexes drive autoreactive B-1a cell responses and autoantibody production both in-vitro and in mouse models.

26 Apr 2011

Signaling pathway reveals mechanism for B cell differentiation in immune response

An article in Science Signaling by researchers at the RIKEN Research Center for Allergy and Immunology (RCAI) has clarified for the first time the mechanism governing differentiation of B cells into antibody-producing plasma cells. The finding establishes a role for the extracellular signal-regulated kinase (ERK) signaling pathway in B cell differentiation, a key step toward the development of B cell-targeted drugs for treatment of autoimmune diseases and allergies.

25 Apr 2011

Kadmon Pharmaceuticals and Nano Terra announce worldwide licensing agreement

Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra’s drug discovery platform, Pharmacomer™ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences (“NT Life”), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.

25 Apr 2011

Valuable insight into immune response

An article in Science Signaling by researchers at the RIKEN Research Center for Allergy and Immunology has clarified for the first time the mechanism governing differentiation of B cells into antibody-producing plasma cells.

22 Apr 2011

Autoimmune Disease News and Research

Further Reading

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

African Americans with SLE have higher antibody response to influenza vaccination: Study

EMA CHMP issues positive opinion for marketing approval of BENLYSTA

Thermo Fisher Scientific to acquire Phadia for €2.47 billion

USPTO grants four key patents for Alvine's proteases to detect celiac disease

Amylin, JDRF collaborate to investigate combination therapy for type 1 diabetes treatment

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Nexvax2- coeliac disease vaccine shows promising results in Phase I clinical trial

Season-of-birth factors can cause celiac disease in Massachusetts children

Lupus Foundation of America introduces new Web site

FDA accepts SGEN's brentuximab vedotin BLAs for Hodgkin lymphoma, ALCL treatment

Journal Blood publishes MacroGenics' DART antibody technology preclinical data

Study explores link between alexithymia and auto-immune disease

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

Study finds gender difference in immune responses to PTSD

Researchers discover molecular mechanisms behind autoimmunity

Signaling pathway reveals mechanism for B cell differentiation in immune response

Kadmon Pharmaceuticals and Nano Terra announce worldwide licensing agreement

Valuable insight into immune response

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News